When a person diagnosed with non-Hodgkin’s lymphoma files a lawsuit against the makers of Roundup, the case does not automatically become a cancer verdict just because a scientific agency somewhere called the chemical a probable carcinogen. Courts operate on a different standard. They do not ask whether glyphosate might cause cancer in some broad theoretical sense. They ask whether the specific evidence in front of them, from expert witnesses, epidemiological studies, and the plaintiff’s own medical history, makes it more likely than not that Roundup caused that person’s disease. This is called legal causation, and it is far more demanding than a lab finding or a regulatory warning.
The most important thing to understand is that courts do not accept scientific conclusions wholesale. Instead, they apply rules for admissibility of expert testimony. In the United States, federal courts follow the standard set in the 1993 case Daubert v. Merrell Dow Pharmaceuticals. Under that rule, a judge acts as a gatekeeper. Before a jury ever hears an expert claim that glyphosate causes cancer, the judge must decide whether the methodology behind that claim is sound. Has the expert published in peer-reviewed journals? Did they use reliable data? Can they explain why their conclusion is generally accepted in the scientific community? If the answer to these questions is no, the expert is excluded, and the case often collapses.
This is why the outcomes of Roundup trials have been so inconsistent across courts. For example, in the first major trial, Johnson v. Monsanto, a jury awarded a dying groundskeeper a staggering $289 million in punitive damages. But in later cases, judges in other jurisdictions reached opposite conclusions. Some courts ruled that the plaintiff’s experts had not proven a causal link between glyphosate and non-Hodgkin’s lymphoma. Others allowed the same experts to testify, leading to jury verdicts against Monsanto. The difference was rarely about the facts of exposure. It was about how each judge applied the Daubert standard to the scientific evidence.
Scientific evidence itself is divided. The International Agency for Research on Cancer (IARC) classified glyphosate as “probably carcinogenic to humans” in 2015, based on limited evidence in humans and sufficient evidence in animals. But the Environmental Protection Agency and the European Food Safety Authority concluded that glyphosate is not likely to be carcinogenic to humans at exposure levels permitted in agriculture. Health Canada and the German Federal Institute for Risk Assessment also found no causal link. So when a plaintiff’s attorney presents IARC’s classification, the defense counters with these contradictory regulatory findings. The jury is left with a battle of experts, not a clear scientific consensus.
What tips the scale in a plaintiff’s favor? Proximity and intensity of exposure. A court is far more convincing to hear a case from a landscaper who sprayed Roundup hundreds of times a year for decades than from a homeowner who used it once each summer. The plaintiff also needs a specific diagnosis that matches the cancer types linked to glyphosate in some studies—most notably non-Hodgkin’s lymphoma, including subtypes like diffuse large B-cell lymphoma. If the plaintiff has a different cancer, or if they have other major risk factors like a history of smoking or a genetic condition, the defense will argue that those factors, not glyphosate, caused the disease. Juries are instructed to weigh all possible causes, and they often find alternative explanations more persuasive.
Another key point is that causation is not the same as association. A statistical association between glyphosate and cancer in a large population does not prove that any single person’s cancer came from the chemical. Courts require specific causation, which means expert testimony that bridges the gap from the general to the individual. This typically involves calculating cumulative exposure, looking at latency periods, and ruling out other likely causes. It is a tall order. Many plaintiffs have lost not because glyphosate is safe, but because their specific case lacked the evidence needed to meet that burden.
The legal landscape also changes with appeals. A big jury verdict in one district can be overturned on appeal if the reviewing court finds that the expert testimony was improperly admitted. That happened in a prominent Roundup case where the Ninth Circuit overruled the judge’s decision to allow a plaintiff’s expert. Conversely, other appellate courts have upheld verdicts for plaintiffs, creating what looks like a legal patchwork. This is confusing for ordinary people, but it is the system working as designed. Courts do not bow to public pressure. They scrutinize each piece of evidence, each study, and each expert’s resume.
If you are considering a claim, you should not assume that because you have cancer and used Roundup, you will automatically win. You need a lawyer who understands how to present causation evidence in a way that survives judicial review. That means finding experts with solid credentials, documenting your exposure history in detail, and honestly confronting other risk factors. It also means preparing for the possibility that a judge might exclude your key scientific witness, which would end the case right there. The bottom line is that legal causation is a demanding hurdle. It is not enough to point at a warning label in a foreign country or a single carcinogen classification. You must prove to a judge and, eventually, a jury that glyphosate was a substantial factor in your cancer. That is what courts decide, and that is why outcomes vary.
